SCHEMBL2271190

SCHEMBL2271190

O=C(Nc1cc(SCc2ccccc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.64
BCL2A1 Q16548 2/20 0.64
MAPT P10636 6/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
PKM P14618 2/20 0.56
GRIK1 P39086 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
KDM4E B2RXH2 6/20 0.56
LTC4S Q16873 1/20 0.52
NPSR1 Q6W5P4 3/20 0.50
HPGD P15428 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HDAC3 O15379 2/20 0.50
NCOR1 O75376 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50
HTT P42858 2/20 0.49
LMNA P02545 1/20 0.49
KCNK2 O95069 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273993 0.88 KDM4E (0.55) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL2272413 0.87 MEN1 (0.63) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL2270296 0.81 TDP1 (0.62) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL18152547 0.78 MCL1 (1.00) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL2271422 0.78 LTC4S (0.74) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL2275929 0.78 KMT2A (0.62) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL14075273 0.78 KDM4E (0.63) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL6350712 0.77 AKR1C2 (0.63) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL4219750 0.76 MCL1 (0.50) MCL1BCL2A1MAPTMEN1KMT2A
SCHEMBL25894123 0.76 MCL1 (0.54) MCL1BCL2A1MAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MCL1 1774/4885BCL2A1 279/4885MAPT 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.